Abstract
We have recently reported that interleukin-8 (IL-8) expression was inversely correlated to estrogen receptor (ER) status and was overexpressed in invasive breast cancer cells. In the present study, we show that IL-8 overexpression in breast cancer cells involves a higher transcriptional activity of IL-8 gene promoter. Cloning of IL-8 promoter from MDA-MB-231 and MCF-7 cells expressing high and low levels of IL-8, respectively, shows the integrity of the promoter in both cell lines. Deletion and site-directed mutagenesis of the promoter demonstrate that NF-κB and AP-1 and to a lesser extent C/EBP binding sites play a crucial role in the control of IL-8 promoter activity in MDA-MB-231 cells. Knockdown of NF-κB and AP-1 activities by adenovirus-mediated expression of an NF-κB super-repressor and RNA interference, respectively, decreased IL-8 expression in MDA-MB-231 cells. On the contrary, restoration of Fra-1, Fra-2, c-Jun, p50, p65, C/EBPα and C/EBPβ expression levels in MCF-7 cells led to a promoter activity comparable to that observed in MDA-MB-231 cells. Our data constitute the first extensive study of IL-8 gene overexpression in breast cancer cells and suggest that the high expression of IL-8 in invasive cancer cells requires a complex cooperation between NF-κB, AP-1 and C/EBP transcription factors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout








Similar content being viewed by others
References
Bharti AC and Aggarwal BB . (2002). Biochem. Pharmacol., 64, 883–888.
Brew R, Southern SA, Flanagan BF, McDicken IW and Christmas SE . (1996). Eur. J. Cancer, 32A, 2142–2147.
Brown PH, Alani R, Preis LH, Szabo E and Birrer MJ . (1993). Oncogene, 8, 877–886.
Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP and Kreutzer DL . (1998). Urology, 51, 161–167.
Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, Vignon F and Lazennec G . (2003). Oncogene, 22, 256–265.
Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C and Chiao PJ . (2003). Clin. Cancer Res., 9, 346–354.
Gilmore T, Gapuzan ME, Kalaitzidis D and Starczynowski D . (2002). Cancer Lett., 181, 1–9.
Haller D, Russo MP, Sartor RB and Jobin C . (2002). J. Biol. Chem., 277, 38168–38178.
He TC, Zhou S, da Costa LT, Yu J, Kinzler KW and Vogelstein B . (1998). Proc. Natl. Acad. Sci. USA, 95, 2509–2514.
Kunsch C and Rosen CA . (1993). Mol. Cell. Biol., 13, 6137–6146.
Kunsch C, Lang RK, Rosen CA and Shannon MF . (1994). J. Immunol., 153, 153–164.
Lazennec G, Bresson D, Lucas A, Chauveau C and Vignon F . (2001). Endocrinology, 142, 4120–4130.
Le X, Shi Q, Wang B, Xiong Q, Qian C, Peng Z, Li XC, Tang H, Abbruzzese JL and Xie K . (2000). J. Interferon Cytokine Res., 20, 935–946.
Lin Y, Huang R, Chen L, Li S, Shi Q, Jordan C and Huang RP . (2004). Int. J. Cancer, 109, 507–515.
Masuya D, Huang C, Liu D, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S, Haba R and Yokomise H . (2001). Cancer, 92, 2628–2638.
Milde-Langosch K, Loning T and Bamberger AM . (2003). Breast Cancer Res. Treat., 79, 175–185.
Milligan L, Antoine E, Bisbal C, Weber M, Brunel C, Forne T and Cathala G . (2000). Oncogene, 19, 5810–5816.
Mukaida N, Okamoto S, Ishikawa Y and Matsushima K . (1994). J. Leukoc. Biol., 56, 554–558.
Mukaida N, Shiroo M and Matsushima K . (1989). J. Immunol., 143, 1366–1371.
Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ and Sledge Jr GW . (1997). Mol. Cell. Biol., 17, 3629–3639.
Newton TR, Patel NM, Bhat-Nakshatri P, Stauss CR, Goulet Jr RJ and Nakshatri H . (1999). J. Biol. Chem., 274, 18827–18835.
Nurnberg W, Tobias D, Otto F, Henz BM and Schadendorf D . (1999). J. Pathol., 189, 546–551.
Osborne CK . (1998). Breast Cancer Res. Treat., 51, 227–238.
Patel PS, Varney ML, Dave BJ and Singh RK . (2002). J. Interferon Cytokine Res., 22, 427–435.
Philips A, Teyssier C, Galtier F, Riviercovas C, Rey JM, Rochefort H and Chalbos D . (1998). Mol. Endocrinol., 12, 973–985.
Roebuck KA . (1999). J. Interferon Cytokine Res., 19, 429–438.
Sheikh MS, Garcia M, Pujol P, Fontana JA and Rochefort H . (1994). Invasion Metastasis, 14, 329–336.
Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM and Sonenshein GE . (1997). J. Clin. Invest., 100, 2952–2960.
Wardell SE, Boonyaratanakornkit V, Adelman JS, Aronheim A and Edwards DP . (2002). Mol. Cell. Biol., 22, 5451–5466.
Xie K . (2001). Cytokine Growth Factor Rev., 12, 375–391.
Xu L and Fidler IJ . (2000). Oncol. Res., 12, 97–106.
Yasumoto K, Okamoto S, Mukaida N, Murakami S, Mai M and Matsushima K . (1992). J. Biol. Chem., 267, 22506–22511.
Zerbini LF, Wang Y, Cho J-Y and Libermann TA . (2003). Cancer Res., 63, 2206–2215.
Acknowledgements
We are grateful to Drs BS Katzenellenbogen, H Nakshatri, C Pothoulakis, DP Edwards, WC Greene, A Le Cam and C Jobin for the gift of plasmids and adenoviruses. This work was supported by grants from ARC (Association pour la Recherche contre le Cancer, Grant No. 4302 (GL) and Grant No. 5825 (DC)) and la Ligue Nationale contre le Cancer (Comite du Gard).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Freund, A., Jolivel, V., Durand, S. et al. Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene 23, 6105–6114 (2004). https://doi.org/10.1038/sj.onc.1207815
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.onc.1207815
Keywords
This article is cited by
-
Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk
Cancer Cell International (2022)
-
An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer
Molecular Biology Reports (2021)
-
Iroquois homeobox 2 suppresses cellular motility and chemokine expression in breast cancer cells
BMC Cancer (2015)
-
High incidence of triple negative breast cancers following pregnancy and an associated gene expression signature
SpringerPlus (2015)
-
PKCη promotes senescence induced by oxidative stress and chemotherapy
Cell Death & Disease (2014)